Cargando…

Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy

We developed a model for improving the prediction of survival outcome using postoperative Ki-67 value in combination with residual cancer burden (RCB) in patients with breast cancer (BC) who underwent neoadjuvant chemotherapy (NAC). We analyzed the data from BC patients who underwent NAC between 201...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ji-Yeon, Oh, Jung Min, Lee, Se Kyung, Yu, Jonghan, Lee, Jeong Eon, Kim, Seok Won, Nam, Seok Jin, Park, Yeon Hee, Ahn, Jin Seok, Kim, Kyunga, Im, Young-Hyuck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209701/
https://www.ncbi.nlm.nih.gov/pubmed/35747813
http://dx.doi.org/10.3389/fonc.2022.903372
_version_ 1784730002990825472
author Kim, Ji-Yeon
Oh, Jung Min
Lee, Se Kyung
Yu, Jonghan
Lee, Jeong Eon
Kim, Seok Won
Nam, Seok Jin
Park, Yeon Hee
Ahn, Jin Seok
Kim, Kyunga
Im, Young-Hyuck
author_facet Kim, Ji-Yeon
Oh, Jung Min
Lee, Se Kyung
Yu, Jonghan
Lee, Jeong Eon
Kim, Seok Won
Nam, Seok Jin
Park, Yeon Hee
Ahn, Jin Seok
Kim, Kyunga
Im, Young-Hyuck
author_sort Kim, Ji-Yeon
collection PubMed
description We developed a model for improving the prediction of survival outcome using postoperative Ki-67 value in combination with residual cancer burden (RCB) in patients with breast cancer (BC) who underwent neoadjuvant chemotherapy (NAC). We analyzed the data from BC patients who underwent NAC between 2010 and 2019 at Samsung Medical Center and developed our residual proliferative cancer burden (RPCB) model using semi-quantitative Ki-67 value and RCB class. The Cox proportional hazard model was used to develop our RPCB model according to disease free survival (DFS) and overall survival (OS). In total, 1,959 patients were included in this analysis. Of 1,959 patients, 905 patients were excluded due to RCB class 0, and 32 were due to a lack of Ki-67 data. Finally, an RPCB model was developed using data from 1,022 patients. The RPCB score was calculated for DFS and OS outcomes, respectively (RPCB-DFS and RPCB-OS). For further survival analysis, we divided the population into 3 classes according to the RPCB score. In the prediction of DFS, C-indices were 0.751 vs 0.670 and time-dependent areas under the receiver operating characteristic curves (AUCs) at 3-year were 0.740 vs 0.669 for RPCB-DFS and RCB models, respectively. In the prediction of OS, C-indices were 0.819 vs 0.720 and time-dependent AUCs at 3-year were 0.875 vs 0.747 for RPCB-OS and RCB models, respectively. The RPCB model developed using RCB class and semi-quantitative Ki-67 had superior predictive value for DFS and OS compared with that of RCB class. This prediction model could provide the basis to decide risk-stratified treatment plan for BC patients who had residual disease after NAC.
format Online
Article
Text
id pubmed-9209701
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92097012022-06-22 Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy Kim, Ji-Yeon Oh, Jung Min Lee, Se Kyung Yu, Jonghan Lee, Jeong Eon Kim, Seok Won Nam, Seok Jin Park, Yeon Hee Ahn, Jin Seok Kim, Kyunga Im, Young-Hyuck Front Oncol Oncology We developed a model for improving the prediction of survival outcome using postoperative Ki-67 value in combination with residual cancer burden (RCB) in patients with breast cancer (BC) who underwent neoadjuvant chemotherapy (NAC). We analyzed the data from BC patients who underwent NAC between 2010 and 2019 at Samsung Medical Center and developed our residual proliferative cancer burden (RPCB) model using semi-quantitative Ki-67 value and RCB class. The Cox proportional hazard model was used to develop our RPCB model according to disease free survival (DFS) and overall survival (OS). In total, 1,959 patients were included in this analysis. Of 1,959 patients, 905 patients were excluded due to RCB class 0, and 32 were due to a lack of Ki-67 data. Finally, an RPCB model was developed using data from 1,022 patients. The RPCB score was calculated for DFS and OS outcomes, respectively (RPCB-DFS and RPCB-OS). For further survival analysis, we divided the population into 3 classes according to the RPCB score. In the prediction of DFS, C-indices were 0.751 vs 0.670 and time-dependent areas under the receiver operating characteristic curves (AUCs) at 3-year were 0.740 vs 0.669 for RPCB-DFS and RCB models, respectively. In the prediction of OS, C-indices were 0.819 vs 0.720 and time-dependent AUCs at 3-year were 0.875 vs 0.747 for RPCB-OS and RCB models, respectively. The RPCB model developed using RCB class and semi-quantitative Ki-67 had superior predictive value for DFS and OS compared with that of RCB class. This prediction model could provide the basis to decide risk-stratified treatment plan for BC patients who had residual disease after NAC. Frontiers Media S.A. 2022-06-07 /pmc/articles/PMC9209701/ /pubmed/35747813 http://dx.doi.org/10.3389/fonc.2022.903372 Text en Copyright © 2022 Kim, Oh, Lee, Yu, Lee, Kim, Nam, Park, Ahn, Kim and Im https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Kim, Ji-Yeon
Oh, Jung Min
Lee, Se Kyung
Yu, Jonghan
Lee, Jeong Eon
Kim, Seok Won
Nam, Seok Jin
Park, Yeon Hee
Ahn, Jin Seok
Kim, Kyunga
Im, Young-Hyuck
Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy
title Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy
title_full Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy
title_fullStr Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy
title_full_unstemmed Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy
title_short Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy
title_sort improved prediction of survival outcomes using residual cancer burden in combination with ki-67 in breast cancer patients underwent neoadjuvant chemotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209701/
https://www.ncbi.nlm.nih.gov/pubmed/35747813
http://dx.doi.org/10.3389/fonc.2022.903372
work_keys_str_mv AT kimjiyeon improvedpredictionofsurvivaloutcomesusingresidualcancerburdenincombinationwithki67inbreastcancerpatientsunderwentneoadjuvantchemotherapy
AT ohjungmin improvedpredictionofsurvivaloutcomesusingresidualcancerburdenincombinationwithki67inbreastcancerpatientsunderwentneoadjuvantchemotherapy
AT leesekyung improvedpredictionofsurvivaloutcomesusingresidualcancerburdenincombinationwithki67inbreastcancerpatientsunderwentneoadjuvantchemotherapy
AT yujonghan improvedpredictionofsurvivaloutcomesusingresidualcancerburdenincombinationwithki67inbreastcancerpatientsunderwentneoadjuvantchemotherapy
AT leejeongeon improvedpredictionofsurvivaloutcomesusingresidualcancerburdenincombinationwithki67inbreastcancerpatientsunderwentneoadjuvantchemotherapy
AT kimseokwon improvedpredictionofsurvivaloutcomesusingresidualcancerburdenincombinationwithki67inbreastcancerpatientsunderwentneoadjuvantchemotherapy
AT namseokjin improvedpredictionofsurvivaloutcomesusingresidualcancerburdenincombinationwithki67inbreastcancerpatientsunderwentneoadjuvantchemotherapy
AT parkyeonhee improvedpredictionofsurvivaloutcomesusingresidualcancerburdenincombinationwithki67inbreastcancerpatientsunderwentneoadjuvantchemotherapy
AT ahnjinseok improvedpredictionofsurvivaloutcomesusingresidualcancerburdenincombinationwithki67inbreastcancerpatientsunderwentneoadjuvantchemotherapy
AT kimkyunga improvedpredictionofsurvivaloutcomesusingresidualcancerburdenincombinationwithki67inbreastcancerpatientsunderwentneoadjuvantchemotherapy
AT imyounghyuck improvedpredictionofsurvivaloutcomesusingresidualcancerburdenincombinationwithki67inbreastcancerpatientsunderwentneoadjuvantchemotherapy